<DOC>
	<DOCNO>NCT01933256</DOCNO>
	<brief_summary>HIP2B develop treatment type 1 type 2 diabetes mellitus . The purpose study investigate safety tolerability repeat dose HIP2B subject type 2 diabetes mellitus . The study also assess whether islet β-cell number function increase time response repeat HIP2B injection .</brief_summary>
	<brief_title>Study Subcutaneous Doses HIP2B Subjects With Type 2 Diabetes Mellitus Treated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adults age 30 65 year , inclusive Males female Diagnosis type 2 diabetes mellitus prior screen meet follow criterion : 1 . Body mass index &lt; 45 kg/m2 2 . HbA1c value &gt; 6.5 &lt; 9.5 % 3 . Cpeptide ≥1.0 ng/mL 4 . On stable dose metformin 12 week Ability provide write informed consent willing comply schedule visit , treatment plan , laboratory test study procedure History follow : type 1 diabetes mellitus , diabetic ketoacidosis , episode severe hypoglycemia ( defined change mental status require assistance ) prior 30 day FPG &gt; 260 mg/dL time randomization Current chronic use ( within past 12 week ) insulin , insulin secretagogues include : sulfonylurea , GLP1 analog , DPP4 inhibitor , meglitinides , αglucosidase inhibitor , pioglitazone , rosiglitazone Glomerular filtration rate ( GFR ) &lt; 60 calculate use Modified Diet Renal Disease equation screen ALT , AST total bilirubin &gt; 2 X ULN Serum amylase concentration &gt; 1.5XULN serum lipase concentration &gt; 2XULN Positive test result glutamic acid decarboxylase antibody ( GADA ) . The presence clinically significant abnormality rest electrocardiogram ( ECG ) Positive HIV , hepatitis B ( HBsAg ) , positive hepatitis C ( HCV Ab ) test screen History clinically significant renal , hepatic , cardiovascular , neurological , gastrointestinal disease could impact patient safety investigator 's opinion Serum triglycerides &gt; 500 mg/dL Presence history cancer within past 5 year exception adequately treat localized basal cell skin cancer situ uterine cervical cancer History weight loss &gt; 5 % 8 week prior randomization subject weight loss program maintenance phase Use weight loss medication within 8 week randomization Uncontrolled hypertension define blood pressure &gt; 160/100 mmHg , use appropriately size cuff , rest History evidence multiple organ autoimmune disorder History thyroid dysfunction hypothyroidism treat stable dose thyroid hormone euthyroid screen History presence acute chronic pancreatitis symptomatic recurrent gallstone Has undergone surgery within 6 month screen plan undergo surgery study period Use parenterally administer protein antibody within 12 week screen . ( Note : Influenza vaccine allow . ) Prior exposure investigational agent participation investigational trial within 30 day prior Day 1 Blood loss blood donation &gt; 500 ml 2 month prior screen . Use systemic longacting corticosteroid within two month prolong use ( one week ) systemic corticosteroid inhale corticosteroid ( daily dosage &gt; 1000 mcg equivalent beclomethasone ) within 30 day prior screen visit . Drugs potential affect ( either increase decrease ) endogenous insulin secretion insulin sensitivity include corticosteroid ( detail ) , βadrenergic blocker , betaadrenergic agonist , quinine , thiazide thiazidelike diuretic , calcineurin inhibitor , niacin , antipsychotic antidepressant drug , somatostatin analog , growth hormone , weightreducing drug ( e.g . orlistat , phentermine topiramate extendedrelease , lorcaserin ) . Stable dos agent commonly required subject T2DM include angiotensin convert enzyme inhibitor , angiotensin II receptor blocker , statin , fibrates , aspirin ( &lt; 100 mg daily ) permit discretion investigator . A serious adverse reaction hypersensitivity drug , unless reaction deem irrelevant study investigator sponsor . History alcohol abuse drug abuse within previous 12 month . No history medical recreational use marijuana within previous 12 month . A history smoking onehalf pack cigarette per day within last 12 month History stroke , transient ischemic attack myocardial infarction within 6 month prior screen . History New York Heart Association Class IIIV heart failure prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>HIP2B</keyword>
	<keyword>Placebo</keyword>
	<keyword>islet β cell</keyword>
</DOC>